REPROCELL INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 137 JPY | -3.52% |
|
-3.52% | -21.71% |
| Sales 2024 * | 2.63B 17.02M | Sales 2025 * | 2.96B 19.15M | Capitalization | 12.52B 80.99M |
|---|---|---|---|---|---|
| Net income 2024 * | -260M -1.68M | Net income 2025 * | -170M -1.1M | EV / Sales 2024 * | 2.45 x |
| Net cash position 2024 * | 6.08B 39.33M | Net cash position 2025 * | 5.83B 37.72M | EV / Sales 2025 * | 2.26 x |
| P/E ratio 2024 * |
-46.6
x | P/E ratio 2025 * |
-71
x | Employees | 92 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.41% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.52% | ||
| 1 week | -3.52% | ||
| Current month | -13.84% | ||
| 1 month | -14.38% | ||
| 3 months | -16.97% | ||
| 6 months | -40.17% | ||
| Current year | -21.71% |
1 week
132.00
142.00
1 month
132.00162.00
Current year
132.00180.00
1 year
132.00329.00
3 years
132.00456.00
5 years
132.00547.00
10 years
132.001 080.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shigetomo Akano
DFI | Director of Finance/CFO | 42 | 20-11-10 |
| President | 56 | 04-06-30 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 15-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 08-05-31 | |
| President | 56 | 04-06-30 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 15-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 137 | -3.52% | 475 300 |
| 24-04-18 | 142 | +4.41% | 442,700 |
| 24-04-17 | 136 | -2.16% | 616,600 |
| 24-04-16 | 139 | 0.00% | 468,500 |
| 24-04-15 | 139 | -2.11% | 685,700 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT
More quotes
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.71% | 80.97M | |
| -5.99% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +51.08% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -3.82% | 8.07B |
- Stock Market
- Equities
- 4978 Stock
